Based on MRS analysis, a new radiotherapy plan for GBM was developed.

Anne Laprie, of the Oncology Radiology Department at the Claudius Institute at the University of Toulouse in France, and others designed radiotherapy Phase III. clinical trials based on magnetic resonance wave spectrometry (MRS)CHO/NAA ratios for "dose mapping" - SPECTRO-GLIO (NCT01507506), published in the February 2019 issue of BMC Cancer.
- excerpted from the chapter of the article: Laprie A, et al. BMC Cancer. 2019 Feb 21;19 (1):167. doi: 10.1186/s12885-019-5317-x. Research background Glioblastoma (GBM) is a highly malignant brain tumor.
may improve the survival of GBM patients, but the prognostics are still very poor, with an overall postoperative survival of only 8-14 months.
Anne Laprie of the Oncology Radiology Department at the Claudius Institute at the University of Toulouse, France, and others designed additional target areas based on magnetic resonance spectrometry (MRS) CHO/NAA ratios for radiotherapy Phase III. phase III clinical trial SPECTRO-GLIO (NCT01507506), published in the February 2019 issue of BMC Cancer.
the multi-center, two-arm, randomized controlled Phase III clinical trial were automatically generated by computers.
the A arm group, i.e. the control group used 3D conformal radiotherapy (3D-CRT) or intensive adaptive radiation therapy (intensity-modulated radiotherapy, IMRT), the 60Gy radiation dose was treated in 30 doses to the MRI intensive area and the tumor week 2 cm area, while six courses of antimony assisted chemotherapy were performed.
B arm group, i.e. the experimental group, based on the above treatment plan, increased the radiation to 72Gy/2.4Gy based on an additional target area of 1 cm outside the area of CHO/NAA>2 on MRS.
results included criteria for inclusion of the subjects, including adults diagnosed with primary GBM in tumor pathology for excision or biopsy, with MGMT gene methylation, early postoperative MRI or CT scans and radiation therapy within 45 days of surgery.
exclude patients who are unable to complete MRI spectrometry, multi-center glioblastoma, have previously received radiotherapy or chemotherapy, accompanied by seizures, meninges metastasis, and renal insefix.
the main indicators to evaluate the therapeutic effect were the overall survival period, and other indicators included the survival without tumor progression, and the dose effect side reactions, including high craniofacial pressure, local necrotasia and seizures.
article introduces the specific outline method of radiotherapy target area, the total course of radiotherapy does not exceed 48 days.
The clinical trial is under way and plans to recruit 220 patients with primary glioblastoma.
this is one of the rare clinical trial studies in Europe to explore the therapeutic dose of GBM radiotherapy, and the targeting method based on MRS is likely to prolong the survival of GBM patients and have an important impact on future treatment.
: The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be used with a license, the source must also be indicated.
welcome to forward and share.
.